432016-21-2

Basic information

• Product Name: methyl 4-methyl-3-((4-methylphenyl)sulfonamido)benzoate
• Synonyms: methyl 4-methyl-3-((4-methylphenyl)sulfonamido)benzoate
• CAS NO: 432016-21-2
• Molecular Weight: 319.381
• Mol File: 432016-21-2.mol

Chemical Properties

• CAS DataBase Reference: methyl 4-methyl-3-((4-methylphenyl)sulfonamido)benzoate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 4-methyl-3-((4-methylphenyl)sulfonamido)benzoate(432016-21-2)
• EPA Substance Registry System: methyl 4-methyl-3-((4-methylphenyl)sulfonamido)benzoate(432016-21-2)

Safety Data

• Hazardous Substances Data: 432016-21-2(Hazardous Substances Data)

Upstream product

• 18595-18-1 3-amino-4-methyl benzoic acid methyl ester 
• 98-59-9 p-toluenesulfonyl chloride 

Downstream Products

• 1309477-83-5 methyl 3-(N,4-dimethylphenylsulfonamido)-4-methylbenzoate 

Relevant articles and documents

Metal-Free Catalyzed Cyclization of N-Methoxybenzamides to Construct Quaternary Carbon-Containing Isoindolinones

Through the intramolecular cyclization of N-methoxybenzamides, a simple and efficient method for constructing valuable isoindolinones under metal-free conditions was developed. The reaction was featured by employing low-cost catalyst, simple operation, 100% atomic economy and excellent regioselectivity. Moreover, a detailed computational study on the reaction system has been performed to clarify the mechanism. This protocol tolerated a variety of functional groups and provided a metal-free protocol for the synthesis of chromane- or tetrahydroquinoline-fused isoindolinones in good yields.

Pyrazole compound, preparation method and application thereof, and pharmaceutical composition

The invention relates to a substituted pyrazole compound, a preparation method and application thereof, and a pharmaceutical composition, wherein the pyrazole compound is represented by a formula (I),is an STAT3 signal channel inhibitor, and can be used for preventing and/or treating diseases related to STAT3 activity, such as tumors, autoimmune diseases, kidney diseases, cardiovascular diseases,inflammatory diseases, metabolic/endocrine dysfunction or neurological diseases.

Toluidinesulfonamide hypoxia-induced factor 1 inhibitors: Alleviating drug-drug interactions through use of pubchem data and comparative molecular field analysis guided synthesis

Inhibitors of hypoxia-inducible factor 1 (HIF-1) represent promising anticancer therapeutics. We have identified a series of potent toluidinesulfonamide HIF-1 inhibitors. However, the series was threatened by a potential liability to inhibit CYP2C9 which could cause dangerous drug-drug interactions when being coadministered with other drugs. We used structure-activity data from the PubChem database to develop a topomer CoMFAmodel that guided the design of novel sulfonamides with high selectivity for HIF-1 over CYP2C9 inhibition.

INHIBITORS OF CELL PROLIFERATION AND USES THEREOF

The present invention provides novel compounds that inhibit cell proliferation and uses of these compounds for treating, ameliorating or preventing diseases, conditions or disorders benefiting from the inhibition hyperproliferation.